MW-501
Cognitive Impairment associated with Schizophrenia (CIAS)
Pre-clinicalDiscovery
Key Facts
Indication
Cognitive Impairment associated with Schizophrenia (CIAS)
Phase
Pre-clinical
Status
Discovery
Company
About MindWalk Holdings
MindWalk Holdings is a clinical-stage biopharmaceutical company dedicated to addressing unmet needs in central nervous system (CNS) disorders. The company's strategy is built on a unique technology platform designed to modulate specific neural pathways with improved safety and efficacy profiles. Its lead programs are advancing in clinical trials for major depressive disorder and Alzheimer's disease. As a public entity, MindWalk aims to translate its scientific insights into transformative treatments for patients with debilitating neurological conditions.
View full company profileTherapeutic Areas
Other Cognitive Impairment associated with Schizophrenia (CIAS) Drugs
| Drug | Company | Phase |
|---|---|---|
| RL-007 | atai Life Sciences | Phase 2 |
| PIPE-307 | Contineum Therapeutics | Phase 2 |